LeMaitre Vascular, Inc.
LMAT Healthcare Medical Instruments & Supplies
LeMaitre Vascular, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $249.6 million, up 13.5% from fiscal 2024. In the quarter to June 2026, revenue grew 9.57%, EPS grew 23.0%, free cash flow fell 28.0% and total debt was flat, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for ten, operating cash flow growth for three.
Follow LMAT
LeMaitre Vascular, Inc. (LMAT) EV/Sales
As of 16 October 2026, LeMaitre Vascular, Inc. (LMAT) trades at a EV/Sales of 6.3×. Over the past ten years it has ranged from 1.4× (January 2015) to 10.9× (November 2024); the current reading is higher than 56% of that period. That is above the Medical Instruments & Supplies industry median of 2.9× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.6× | (25.14%) |
| FY2024 | 8.8× | 45.65% |
| FY2023 | 6.1× | 4.91% |
| FY2022 | 5.8× | (11.71%) |
| FY2021 | 6.5× | 1.80% |
| FY2020 | 6.4× | 8.31% |
| FY2019 | 5.9× | 52.25% |
| FY2018 | 3.9× | (28.35%) |
| FY2017 | 5.4× | 9.64% |
| FY2016 | 5.0× | 39.27% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 7.6× | (15.31%) |
| Mar 2026 | 9.0× | 35.52% |
| Dec 2025 | 6.6× | (12.18%) |
| Sep 2025 | 7.5× | 2.01% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| XRAY DENTSPLY SIRONA Inc. compare | 1.0× |
| NVST Envista Holdings Corporation compare | 1.4× |
| AZTA Azenta, Inc. compare | 2.1× |
| STAA STAAR Surgical Company compare | 2.7× |
| WRBY Warby Parker Inc. compare | 2.9× |
| ATRC AtriCure, Inc. compare | 4.7× |
| LMAT LeMaitre Vascular, Inc. | 6.3× |
| KMTS Kestra Medical Technologies, Ltd. compare | 13.8× |
| PLSE Pulse Biosciences, Inc compare | 2,555× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)